Neoplasm, Residual: all 272 studies
Page 2 of 3. Open to participants first (124), then studies with results posted, then the rest; newest registration first within each.
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
- 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade GliomasNot yet recruitingNCT05850377
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial CarcinomaRecruitingNCT05595408
- Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)RecruitingNCT05534087Phase 3
- Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical CancerRecruitingNCT05531981
- Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRDRecruitingNCT05408897
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsRecruitingNCT05232916Phase 3
- Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.RecruitingNCT05203003
- Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)RecruitingNCT05196087
- Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)RecruitingNCT04991103Phase 2
- Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic LeukemiaRecruitingNCT04977895
- Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease StatusRecruitingNCT04934930Phase 2
- Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast CancerRecruitingNCT04768426Phase 2
- Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04758975Phase 2
- Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)RecruitingNCT04707300Phase 1/2
- Better Leukemia Diagnostics Through AI (BELUGA)RecruitingNCT04466059
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2
- Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative ChemotherapyNot yet recruitingNCT03703427Phase 2
- Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative ChemotherapyNot yet recruitingNCT03684863Phase 2
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantRecruitingNCT03326921Phase 1
- Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast CancerRecruitingNCT02306096
- Modified Vaccine for High Risk or Low Residual Melanoma PatientsRecruitingNCT01898039Phase 1/2
- Caris Biorepository Research ProtocolRecruitingNCT01499394
- A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsCompletedNCT04853017Phase 1Results posted
- Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast CancerCompletedNCT04674306Early Phase 1Results posted
- Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.TerminatedNCT04623216Phase 1/2Results posted
- CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual DiseaseTerminatedNCT04526288Phase 2Results posted
- Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04506086Phase 4Results posted
- Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLActive, not recruitingNCT03863184Phase 2Results posted
- Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell TransplantTerminatedNCT03537599Phase 1/2Results posted
- Intraoperative Detection of Residual Cancer in Breast CancerCompletedNCT03321929Phase 2Results posted
- Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)TerminatedNCT03298412Phase 2Results posted
- Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic MalignanciesTerminatedNCT03272633Early Phase 1Results posted
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03192397Phase 1/2Results posted
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
- CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALLTerminatedNCT02935543Phase 2Results posted
- Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT02767934Phase 2Results posted
- A Phase 1 Study of AMG 330 in Subjects With Myeloid MalignanciesTerminatedNCT02520427Phase 1Results posted
- Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual DiseaseCompletedNCT02458014Phase 2Results posted
- Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell TransplantCompletedNCT02389517Phase 2Results posted
- Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual DiseaseTerminatedNCT02370888Phase 1Results posted
- Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaStatus unknownNCT01894477Phase 2Results posted
- First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With VelcadeCompletedNCT01215344Phase 2Results posted
- Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01207388Phase 2Results posted
- Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive LeukemiaTerminatedNCT01158885Phase 2Results posted
- Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaActive, not recruitingNCT01059786Phase 2Results posted
- Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaActive, not recruitingNCT00923013Phase 2Results posted
- Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual DiseaseTerminatedNCT00863434Phase 2Results posted
- Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT00560794Phase 2Results posted
- Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual DiseaseCompletedNCT00267085Phase 2Results posted
- Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-IIIActive, not recruitingNCT07821333Phase 2
- Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.CompletedNCT07692607Not applicable
- Validation of ESGO Quality Indicators in Advanced Ovarian Cancer SurgeryCompletedNCT07567573
- A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant ChemotherapyActive, not recruitingNCT07136077Phase 2
- A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT07134088Phase 1/2
- MRD in PAAD Adjuvant TherapyActive, not recruitingNCT06867146Not applicable
- Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With LymphomaActive, not recruitingNCT06744075Not applicable
- ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)CompletedNCT06730412
- Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT06668558Phase 2
- Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 TreatmentActive, not recruitingNCT06663787
- Dynamic ctDNA Detection for Colorectal Cancer Liver MetastasesCompletedNCT06404593
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)Active, not recruitingNCT06358430Phase 1
- Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder CancerCompletedNCT06205277
- MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of RelapseCompletedNCT06000306
- Natural Killer(NK) Cell Therapy in Acute Myeloid LeukemiaCompletedNCT05987696Phase 1
- A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid BiopsySuspendedNCT05867901
- Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab ConsolidationStatus unknownNCT05837689
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid LeukemiaWithdrawnNCT05720988Phase 1
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingNCT05708235Phase 2
- Elimination of Minimal Residual Disease After TransplantActive, not recruitingNCT05690984Phase 2
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedNCT05642195Phase 1/2
- Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLCCompletedNCT05637580
- Non-invasive MRD Assessment in Multiple MyelomaCompletedNCT05625971
- A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent PositiveStatus unknownNCT05603156Not applicable
- Natural Killer(NK) Cell Therapy for AML Minimal Residual DiseaseTerminatedNCT05601830Phase 1
- Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple MyelomaStatus unknownNCT05536700
- ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic AdenocarcinomaActive, not recruitingNCT05479708
- Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD EvaluationStatus unknownNCT05460195Phase 2
- A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT05429320Phase 2
- Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaStatus unknownNCT05362942Phase 2
- Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.WithdrawnNCT05321862Phase 2
- Local Radiotherapy for Residual Tumor Lesions During the First-line TreatmentCompletedNCT05205226
- ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLCActive, not recruitingNCT05198154
- Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)Active, not recruitingNCT05182385Phase 1/2
- Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLCStatus unknownNCT05167604
- Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRDStatus unknownNCT05137860Phase 4
- Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic LeukaemiaCompletedNCT05093192Not applicable
- MInimal Residual Disease Adapted StrategyActive, not recruitingNCT04934475Phase 3
- Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)TerminatedNCT04920188
- Minimal Residual Disease: A Trial Using Liquid Biopsies in Solid Malignancies.Active, not recruitingNCT04853420
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingNCT04841148Phase 2
- Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPALCompletedNCT04827745Phase 2
- ALL SCTped 2012 FORUM Add-on Study Blina Post HSCTTerminatedNCT04785547Phase 2
- Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and PevonedistatCompletedNCT04712942Phase 2
- Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid LeukemiaCompletedNCT04679285
- Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)Status unknownNCT04604691Phase 1
- The clonoSEQ® Watch RegistryTerminatedNCT04545333
- Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive ChemotherapyStatus unknownNCT04541277Phase 2
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Phase 1/2